CymaBay Therapeutics Inc. (CBAY)

NASDAQ: CBAY · IEX Real-Time Price · USD
3.15 0.00 (0.00%)
Jan 18, 2022 2:56 PM EST - Market open
Market Cap266.71M
Revenue (ttm)n/a
Net Income (ttm)-79.21M
Shares Out84.67M
EPS (ttm)-1.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume244,351
Open3.13
Previous Close3.15
Day's Range3.08 - 3.18
52-Week Range3.02 - 6.56
Beta1.08
AnalystsStrong Buy
Price Target11.10 (+252.4%)
Earnings DateNov 10, 2021

About CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia...

IndustryPharmaceuticals
CEOSujal Shah
Employees41
Stock ExchangeNASDAQ
Ticker SymbolCBAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CBAY stock is "Strong Buy." The 12-month stock price forecast is 11.10, which is an increase of 252.38% from the latest price.

Price Target
$11.10
(252.38% upside)
Analyst Consensus: Strong Buy

News

CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the Upgrade

CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 week ago - Zacks Investment Research

7 Penny Stocks With the Potential to 10X in 2022

The broader market looks expensive, but these penny stocks provide low-cost opportunities for considerable upside according to analysts. The post 7 Penny Stocks With the Potential to 10X in 2022 appeare...

Other symbols:PAYSSENSSOLOSRGACWBR
1 month ago - InvestorPlace

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies...

2 months ago - GlobeNewsWire

CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies...

2 months ago - GlobeNewsWire

CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biom...

NEWARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients w...

2 months ago - GlobeNewsWire

CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis

Webinar on Monday, November 15th, @ 4:30pm EST Webinar on Monday, November 15th, @ 4:30pm EST

2 months ago - GlobeNewsWire

CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates

CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -13.79% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...

2 months ago - Zacks Investment Research

CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update

Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC)

2 months ago - GlobeNewsWire

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

2 months ago - GlobeNewsWire

CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

2 months ago - GlobeNewsWire

CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update

Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth

5 months ago - GlobeNewsWire

CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021

NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

5 months ago - GlobeNewsWire

CymaBay Secures $100M Non-Dilutive Funding To Fund Seladelpar Development Program

CymaBay Therapeutics Inc (NASDAQ: CBAY) has received $100 million in non-dilutive financing from Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC). U...

5 months ago - Benzinga

CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth

Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC

5 months ago - GlobeNewsWire

New Strong Sell Stocks for July 20th

AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.

Other symbols:AEVABIDUDRNARACE
5 months ago - Zacks Investment Research

CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update

Highly experienced executives, Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer, strengthen the management team

8 months ago - GlobeNewsWire

CymaBay Names Lewis Stuart Chief Commercial Officer

Proven Leader in Building Commercial Organizations to Prepare Markets and Deliver Successful Product Launches  Planning for Seladelpar Launch as it Completes Development and Regulatory Submissions

8 months ago - GlobeNewsWire

CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors

NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea...

9 months ago - GlobeNewsWire

CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update

Actively recruiting patients in two global, clinical studies evaluating seladelpar in primary biliary cholangitis (PBC):

9 months ago - GlobeNewsWire

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021

NEWARK, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic disea...

10 months ago - GlobeNewsWire

5 Disruptive Biotech Stocks With Solid Long-Term Potential

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Other symbols:EDITMRNSNTLAVRTX
1 year ago - Zacks Investment Research

CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 St...

NEWARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients w...

1 year ago - GlobeNewsWire

CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes

The AdventHealth Translational Research Institute (TRI) in Orlando, FL to lead the study, funded by the Helmsley Charitable Trust, evaluating MBX-2982, a GPR119 agonist, for its ability to increase secr...

1 year ago - GlobeNewsWire

CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseas...

1 year ago - GlobeNewsWire

Implied Volatility Surging for CymaBay Therapeutics (CBAY) Stock Options

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research